Abstracts tagged "lupus nephritis and tacrolimus"

Abstract Number: 2638 • 2018 ACR/ARHP Annual Meeting
Tacrolimus Use in Hispanic Patients with Refractory Lupus Nephritis
Phillip Aleksiejuk¹ and Elizabeth Ortiz², ¹Rheumatology, University of Southern California, Los Angeles, CA, ²Department of Rheumatology, University of Southern California, Los Angeles, CA
Background/Purpose: Lupus nephritis is one of the most common and severe manifestations of patients with SLE. Studies assessing the use of Tacrolimus (TAC) in lupus…
Abstract Number: 1795 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-
Tsutomu Takeuchi¹ and Naoko Wakasugi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Astellas Pharma Inc., Tokyo, Japan
Background/Purpose: Tacrolimus (Tac) is an immunosuppressive macrolide that blocks T cell activation by specifically inhibiting calcineurin. Some randomized controlled studies have shown that TAC is an…
Abstract Number: 617 • 2013 ACR/ARHP Annual Meeting
The Potentiality Of Multi-Target Therapy With Cyclophosphamide and Tacrolimus For Lupus Nephritis
Ryota Sakai, Akiko Shibata, Kentaro Chino, Tsuneo Kondo, Ayumi Okuyama, Eiko Nishi, Hirofumi Takei, Hayato Nagasawa and Koichi Amano, Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Background/Purpose: Multi-target therapy for lupus nephritis (LN) had first reported by Bao et al. 2008 regarding the treatment of mixed diffuse proliferative and membranous LN using…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].